Patents Assigned to Pfizer
  • HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS
    Publication number: 20180037571
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), and Parkinson's disease.
    Type: Application
    Filed: October 10, 2017
    Publication date: February 8, 2018
    Applicant: PFIZER INC.
    Inventors: MICHAEL AARON BRODNEY, JENNIFER ELIZABETH DAVOREN, AMY BETH DOUNAY, IVAN VIKTOROVICH EFREMOV, DAVID LAWRENCE FIRMAN GRAY, MICHAEL ERIC GREEN, JACLYN LOUISE HENDERSON, CHEWAH LEE, SCOT RICHARD MENTE, STEVEN VICTOR O'NEIL, BRUCE NELSEN ROGERS, LEI ZHANG
  • Bispecific heterodimeric diabodies and uses thereof
    Patent number: 9884921
    Abstract: Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: February 6, 2018
    Assignee: Pfizer Inc.
    Inventors: Chad Michael May, Adam Reid Root, William A. Brady, Lioudmila Gennadievna Tchistiakova, Lidia Mosyak, Laird Bloom, Paul A. Moore, Leslie S. Johnson
  • Bicyclic-fused heteroaryl or aryl compounds
    Patent number: 9879022
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: January 30, 2018
    Assignee: Pfizer Inc.
    Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
  • Process for preparing therapeutic nanoparticles
    Patent number: 9877923
    Abstract: The present disclosure generally relates to a process for preparing therapeutic nanoparticles, where the process includes combining a therapeutic agent with an organic acid. The therapeutic nanoparticles may have, for example, improved drug loading and/or drug release properties.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: January 30, 2018
    Assignee: Pfizer Inc.
    Inventors: Maria Figueiredo, Erick Peeke, David Dewitt, Christina Van Geen Hoven, Greg Troiano, James Wright, Young-Ho Song, Hong Wang
  • 2-thiopyrimidinones
    Patent number: 9873673
    Abstract: Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: January 23, 2018
    Assignee: Pfizer Inc.
    Inventors: Philip A. Carpino, Edward L. Conn, Robert L. Dow, Matthew S. Dowling, David Hepworth, Daniel Wei-Shung Kung, Suvi Orr, Benjamin N. Rocke, Roger B. Ruggeri, Matthew F. Sammons, Joseph S. Warmus, Yan Zhang
  • 3-indol substituted derivatives, pharmaceutical compositions and methods for use
    Patent number: 9873690
    Abstract: A compound of Formula I is provided: or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also relates to a process for manufacturing compounds of Formula I.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: January 23, 2018
    Assignees: Pfizer Inc, iTeos Therapeutics
    Inventors: Sacha Ninkovic, Stefano Crosignani, Indrawan James McAlpine, Michael Raymond Collins, Stephanie Anne Scales, Andreas Maderna, Martin Wythes
  • Anti-EFNA4 antibody-drug conjugates
    Patent number: 9872922
    Abstract: The present invention provides for anti-EFNA4 antibody-drug conjugates and methods for preparing and using the same.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: January 23, 2018
    Assignees: Pfizer Inc., AbbVie Stemcentrx LLC
    Inventors: Marc Isaac Damelin, Kiran Manohar Khandke, Puja Sapra, Alexander John Bankovich, Scott J. Dylla
  • Stable formulations for lyophilizing therapeutic particles
    Patent number: 9872848
    Abstract: The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: January 23, 2018
    Assignee: Pfizer Inc.
    Inventors: Greg Troiano, Young-ho Song, Stephen E. Zale, James Wright, Christina Van Geen Hoven
  • Drug loaded polymeric nanoparticles and methods of making and using same
    Patent number: 9872913
    Abstract: The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: January 23, 2018
    Assignee: Pfizer Inc.
    Inventors: Greg Troiano, Michael Figa, Abhimanyu Sabnis
  • Heteroaromatic compounds and their use as dopamine D1 ligands
    Patent number: 9868744
    Abstract: The present invention provides, in part, compounds of Formula (I) and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: January 16, 2018
    Assignee: Pfizer Inc.
    Inventors: David Lawrence Firman Gray, Lei Zhang, Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, Chewah Lee, Scot Richard Mente, Steven Victor O'Neil, Bruce Nelsen Rogers, Chakrapani Subramanyam
  • CIRCULATING TUMOR CELL ASSAY
    Publication number: 20180011103
    Abstract: Methods for the detection, enumeration and analysis of circulating tumor cells expressing insulin-like growth factor-1 receptors (IGF-1R) are disclosed. These methods are useful for cancer screening and staging, development of treatment regimens, and for monitoring for treatment responses, cancer recurrence or the like. Test kits that facilitate the detection, enumeration and analysis of such circulating tumor cells are also provided.
    Type: Application
    Filed: July 27, 2017
    Publication date: January 11, 2018
    Applicants: Janssen Diagnostics, LLC, Pfizer Inc.
    Inventors: Antonio GUALBERTO, Maria Luisa PACCAGNELLA, Carrie L. MELVIN, Madeline I. REPOLLET, David CHIANESE, Mark Carle CONNELLY, Leonardus Wendelinus Mathias Marie TERSTAPPEN
  • Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
    Patent number: 9861638
    Abstract: The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: January 9, 2018
    Assignee: PFIZER INC.
    Inventors: Patricia Ann Basford, Anthony Michael Campeta, Adam Gillmore, Matthew Cameron Jones, Eleftherios Kougoulos, Suman Luthra, Robert Walton
  • 5,7-Dihydro-Pyrrolo-Pyridine Derivatives
    Publication number: 20180002331
    Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
    Type: Application
    Filed: June 29, 2017
    Publication date: January 4, 2018
    Applicant: Pfizer Inc.
    Inventors: Lei Zhang, Christopher Ryan Butler, Elizabeth Mary Beck, Michael Aaron Brodney, Matthew Frank Brown, Laura Ann McAllister, Erik Alphie LaChapelle, Adam Matthew Gilbert
  • Immunogenic Compositions for Use in Pneumococcal Vaccines
    Publication number: 20180000922
    Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention thereforerelates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
    Type: Application
    Filed: January 5, 2016
    Publication date: January 4, 2018
    Applicant: Pfizer Inc.
    Inventors: David Cooper, Kathrin Ute Jansen, Michael William Pride
  • ANTI-CXCR4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
    Publication number: 20180002428
    Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.
    Type: Application
    Filed: May 31, 2017
    Publication date: January 4, 2018
    Applicant: PFIZER INC.
    Inventors: Shu-Hui LIU, Flavia Mercer PERNASETTI, Weihsien HO
  • Therapeutic Nanoparticles With High Molecular Weight Copolymers
    Publication number: 20180000885
    Abstract: The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 0.1 to about 40 weight percent of a therapeutic agent and about 10 to about 90 weight percent a diblock poly(lactic) acid-poly(ethylene)glycol copolymer or a diblock poly(lactic)-co-poly(glycolic) acid-poly(ethylene)glycol copolymer, wherein the diblock poly(lactic) acid-poly(ethylene)glycol copolymer comprises poly(lactic) acid having a number average molecule weight of about 30 kDa to about 90 kDa or the diblock poly(lactic)-co-poly(glycolic) acid-poly(ethylene)glycol copolymer comprises poly(lactic)-co-poly(glycolic) acid having a number average molecule weight of about 30 kDa to about 90 kDa.
    Type: Application
    Filed: June 15, 2017
    Publication date: January 4, 2018
    Applicant: Pfizer Inc.
    Inventors: David Dewitt, Maria Conceicao Figueiredo, Hong Wang, Gregory Troiano, Young-Ho Song
  • STABLE AQUEOUS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ANTIBODY FORMULATION
    Publication number: 20180000933
    Abstract: The present invention relates to the field of pharmaceutical formulations of antibodies. Specifically, the present invention relates to a stable liquid antibody formulation and its pharmaceutical preparation and use. This invention is exemplified by an aqueous formulation of an anti-vascular endothelial growth factor (VEGF) antibody.
    Type: Application
    Filed: January 20, 2016
    Publication date: January 4, 2018
    Applicant: Pfizer Inc.
    Inventors: Rebecca Lee Ingram, Sarah Elizabeth Weiser
  • Methyoxy-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof
    Publication number: 20180002330
    Abstract: The present invention provides methoxy-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
    Type: Application
    Filed: January 29, 2016
    Publication date: January 4, 2018
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Andrew Christopher Flick, Peter Jones, Neelu Kaila, Scot Richard Mente, John David Trzupek, Michael L. Vazquez, Goran Mattias Wennerstal, Li Xing, Edouard Zamaratski, Liying Zhang, Rayomand J. Unwalla
  • Heteroaromatic compounds and their use as dopamine D1 ligands
    Patent number: 9856263
    Abstract: The present invention provides, in part, compounds of Formula (I): and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: January 2, 2018
    Assignee: PFIZER INC.
    Inventors: David Lawrence Firman Gray, Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, Scot Richard Mente, Chakrapani Subramanyam
  • N-(2-(2-AMINO-6-SUBSTITUTED-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]OXAZIN-8a(8H)-YL)-THIAZOL-4-YL) AMIDES
    Publication number: 20170369506
    Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, wherein the variables R1, R2, R3, R4 and X are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: August 16, 2017
    Publication date: December 28, 2017
    Applicant: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Christopher Ryan Butler, Lei Zhang, Brian Thomas O'Neill